What China Does Better Than Anywhere Else

The question most patients ask is the wrong one

A patient looking at treatment abroad usually asks which country is cheapest, or which country has the best hospitals. Neither question produces a useful answer. Every country has good hospitals and bad ones, and price comparisons across different health systems rarely compare the same thing.

The question that produces a useful answer is narrower. For this specific treatment, where in the world is the volume highest, the technology most advanced, and the cost low enough to justify a flight.

For a small number of treatments, the answer is China, and the reasons are documented rather than promotional. This article sets out six of them with the underlying figures, and it states plainly where China is not the right choice.

Particle therapy: proton and heavy ion

Particle therapy delivers radiation with a physical property that conventional radiotherapy does not have. Protons and carbon ions deposit most of their energy at a precise depth and almost none beyond it, which means a tumour can receive a high dose while the tissue behind it is spared.

Shanghai Proton and Heavy Ion Hospital is the clearest example in China. It has operated for eleven years with both proton and carbon ion technology, and it published a survival report covering all treated patients. The figures below come from that report and from the hospital's own disclosure to Xinhua in May 2026.

Two observations follow from these figures. The first is that the outcomes are comparable with the established particle centres in Japan and Germany, which is the relevant benchmark. The second is that the hospital has treated more than one hundred patients from outside mainland China, so the pathway for a foreign patient already exists.

A second phase is under construction with a scheduled completion in 2028, adding one carbon ion system and one proton system. When it opens, the hospital expects to be the largest particle therapy centre in the world by capacity.

Shanghai is not the only option. China has more than thirty particle therapy facilities either operating or under construction, which means a patient is not competing for a single slot.

CAR-T cell therapy

CAR-T therapy modifies a patient's own T cells so that they recognise a marker on malignant cells, then returns them after chemotherapy. It is licensed for a small number of blood cancers, principally relapsed or refractory large B-cell lymphoma and certain leukaemias.

China is the largest site of CAR-T clinical research in the world. One analysis counts 1,283 CAR-T clinical trials registered in China, more than any other country. The consequence for patients is not the trial count itself but what follows from it: several domestic products are approved, and the price is a fraction of the United States figure.

The published comparison is between forty thousand and eighty thousand US dollars in China, against four hundred thousand to six hundred thousand in the United States. The gap is structural rather than a discount. Chinese-developed products are priced for the Chinese market, and the hospital and pharmacy costs that make up the remainder are lower.

Two cautions belong here. The first is that the indication matters more than the price. A patient whose cancer does not express the target marker will not benefit, regardless of which country administers the infusion. The second is that the weeks around the infusion require intensive monitoring for cytokine release syndrome and neurological toxicity, which means the patient must stay near the treating hospital rather than fly home.

Liver transplantation

Organ transplantation is the treatment area where volume matters most, because outcomes improve with institutional experience more steeply than in almost any other field.

Chinese transplant centres perform a large number of liver transplants each year. In 2024, Shanghai Renji Hospital performed 581 liver transplants, the highest single-centre volume in the country, followed by the Affiliated Hospital of Qingdao University and the First Affiliated Hospital of Zhejiang University.

Two points must be stated clearly for an international patient. First, the organ allocation system in China prioritises Chinese citizens, and the legal and ethical framework that governs transplantation does not permit the kind of paid organ arrangement that medical tourism advertising in some other countries implies. A foreign patient cannot travel to China expecting to purchase an organ. Second, living-donor transplantation, where a family member donates part of a liver, is the pathway that most often applies to international patients, and it requires evaluation of both the donor and the recipient in China before the operation can be scheduled.

Any provider that offers a liver transplant to a foreign patient without discussing the donor question in detail is not describing a real pathway.

Integrated Chinese and Western medicine

This is the area with no equivalent anywhere else, and it is described in a separate article on this site. The short version is that China operates the only health system in which traditional medicine is a licensed specialty inside the same public hospital as surgery and chemotherapy.

The scale is not marginal. The 2024 national health statistics report 103,704 traditional Chinese medicine institutions, 1.823 million beds, 971,000 licensed practitioners, and 1.68 billion outpatient visits in one year. In the same year, 99.7 percent of community health centres and 99.8 percent of township health centres provided Chinese medicine services.

For a foreign patient, the practical consequence is that a course of acupuncture can be delivered inside the hospital that is also treating the cancer, with both clinicians reading the same record. That arrangement does not exist in most countries, where the two systems are separate businesses that do not communicate.

Comprehensive health screening

A full-body health check in a Chinese tertiary hospital usually completes within one day, with most laboratory and imaging results available within twenty-four to forty-eight hours. The package typically includes blood work, ultrasound, computed tomography, gastroscopy and colonoscopy under sedation where indicated, and a physician consultation at the end.

The cost is the reason patients travel for it. A comprehensive package in a Chinese public hospital usually falls between 400 and 1,200 US dollars, depending on the city and the imaging included. The same set of investigations in the United States, paid privately, typically exceeds several thousand dollars.

This is the least complex service in this list, and the one most often combined with a family trip. It is also the service most often criticised, because a large number of tests performed on an asymptomatic person produces incidental findings that generate anxiety and further investigation. A patient should discuss which components are appropriate for their age and history rather than buying the largest package available.

Dental implants and fertility treatment

Both are high-volume, price-sensitive services where China's cost advantage is real but smaller than for the treatments above.

A single dental implant in a Chinese public hospital typically costs between 420 and 2,100 US dollars depending on the implant brand, against 1,500 to 3,000 in the United States. The implants used are the same international brands, and the procurement receipts can be requested. The caveat is that the treatment requires two visits separated by three to six months, which means either two trips or a longer stay than most patients expect.

A fresh IVF cycle in China costs between 5,500 and 9,000 US dollars including medication, against 12,000 to 25,000 in the United States. Chinese fertility centres handle very large volumes. The regulatory position matters here: treatment is available to married couples, and the documentation requirements for foreign patients are specific. A single patient or a same-sex couple should confirm eligibility before planning travel.

Where China is not the answer

Four situations should send a patient elsewhere, and a provider that does not say so is not trustworthy.

• A treatment that is available at home within a reasonable waiting time and covered by insurance. Travelling adds risk without adding benefit.
• A condition requiring long-term continuity with one clinician. Follow-up across two health systems is difficult, and the risk of a gap in care is real.
• Any situation where the patient cannot travel safely, including unstable cardiac disease or a recent pulmonary embolism.
• Any provider offering an organ, a guarantee of outcome, or a treatment that is not available to Chinese citizens themselves.

How to choose between these

Each of the six areas has a different decision structure. Particle therapy and CAR-T depend on whether the patient's specific disease and stage meet the accepted indication. Transplantation depends on the donor question more than on the hospital. Integrated medicine and health screening are low-risk services that can be added to a trip organised for another reason. Dental and fertility treatment depend on whether the patient can accommodate the required number of visits.

The common thread is that the answer is specific rather than general. China is not the best place for medical treatment in the abstract. It is the best place for a short list of treatments, and a patient who identifies whether their case falls on that list has answered the question that matters.

This article is information, not medical advice. Suitability for any treatment depends on the individual case and belongs to the treating physicians.